{
  "kind": "treatment",
  "slug": "mixed-amphetamine-salts-adderall",
  "type": "stimulant",
  "name": "Mixed Amphetamine Salts (Adderall)",
  "summary": "A central nervous system stimulant used in the treatment of ADHD and narcolepsy.",
  "description": "Mixed amphetamine salts (MAS) are a combination of amphetamine and dextroamphetamine that enhance synaptic levels of dopamine and norepinephrine by promoting release and inhibiting reuptake. They are commonly prescribed for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.",
  "category": "medications/stimulants",
  "tags": [
    "adhd",
    "stimulant",
    "amphetamine",
    "narcolepsy"
  ],
  "metadata": {
    "drug_classes": [
      "CNS Stimulant",
      "Amphetamine"
    ],
    "therapeutic_categories": [
      "ADHD",
      "Narcolepsy"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": true,
    "generic_available": true,
    "brand_names": [
      "Adderall",
      "Adderall XR"
    ],
    "dea_schedule": "II",
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Pediatric",
      "Adult"
    ],
    "treatment_duration": [
      "Short-term",
      "Long-term"
    ],
    "specialty_areas": [
      "Psychiatry",
      "Neurology"
    ],
    "fda_approval_year": 1996
  },
  "clinical_metadata": {
    "primary_indications": [
      "ADHD",
      "Other"
    ],
    "off_label_uses": [
      "Treatment-resistant depression",
      "Cognitive enhancement in select neurologic disorders"
    ],
    "contraindications": [
      "Advanced arteriosclerosis",
      "Symptomatic cardiovascular disease",
      "Moderate to severe hypertension",
      "Hyperthyroidism",
      "Glaucoma",
      "Agitated states",
      "History of drug abuse",
      "MAOI use within 14 days"
    ],
    "monitoring_required": [
      "Blood pressure",
      "Heart rate",
      "Growth in children",
      "Signs of misuse/abuse"
    ],
    "efficacy_rating": {
      "adhd": 5,
      "narcolepsy": 5
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "mixed amphetamine salts",
      "adderall",
      "amphetamine",
      "adhd",
      "stimulant"
    ],
    "synonyms": [
      "MAS",
      "amphetamine-dextroamphetamine"
    ],
    "common_misspellings": [
      "aderall",
      "aderol",
      "addarall"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)",
        "Narcolepsy"
      ]
    },
    {
      "type": "mechanism",
      "text": "Promotes release and blocks reuptake of dopamine and norepinephrine in the CNS."
    },
    {
      "type": "dosing",
      "adult": {
        "adhd": "Start 5 mg once or twice daily; increase by 5 mg weekly to a typical range of 5–40 mg/day divided into 1–3 doses",
        "narcolepsy": "Start 10 mg daily; increase by 10 mg weekly to 60 mg/day in divided doses"
      },
      "pediatric": {
        "adhd_6_and_over": "Start 5 mg once or twice daily; increase by 5 mg weekly; max 40 mg/day"
      },
      "hepatic_impairment": "No specific adjustment; use caution",
      "renal_impairment": "No specific adjustment; use caution"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Immediate-release tablets: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg",
        "Extended-release capsules (Adderall XR): 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "IR: onset 30–60 min, duration 4–6 h; XR: onset 30–60 min, duration up to 12 h."
    },
    {
      "type": "adverse_effects",
      "common": [
        "insomnia",
        "decreased appetite",
        "dry mouth",
        "increased heart rate",
        "nervousness"
      ],
      "less_common": [
        "mood changes",
        "tics",
        "weight loss"
      ],
      "serious": [
        "sudden death in patients with cardiac abnormalities",
        "myocardial infarction",
        "stroke",
        "psychosis",
        "mania"
      ]
    },
    {
      "type": "warnings",
      "black_box": "High potential for abuse and dependence.",
      "other": [
        "Serious cardiovascular events reported with misuse",
        "May exacerbate anxiety, tics, or bipolar disorder",
        "Risk of sudden death in patients with structural cardiac abnormalities"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "MAOIs",
          "risk": "Hypertensive crisis",
          "action": "Contraindicated; 14-day washout"
        },
        {
          "with": "Acidifying agents (ascorbic acid)",
          "risk": "↓ amphetamine levels",
          "action": "May require dose adjustment"
        },
        {
          "with": "Alkalinizing agents (sodium bicarbonate)",
          "risk": "↑ amphetamine levels",
          "action": "Use caution"
        },
        {
          "with": "Other stimulants",
          "risk": "Additive cardiovascular and CNS effects",
          "action": "Avoid or monitor closely"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Blood pressure and heart rate at baseline and during therapy",
        "Growth in pediatric patients",
        "Signs of misuse, abuse, or diversion"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if potential benefit justifies risk",
      "lactation": "Excreted in breast milk; avoid if possible",
      "pediatrics": "Approved for children ≥6 years",
      "geriatrics": "Use with caution due to higher cardiovascular risk"
    },
    {
      "type": "tapering",
      "text": "Taper gradually if discontinuing to minimize withdrawal symptoms such as extreme fatigue, depression, and sleep disturbances."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Extended-release formulation provides smoother symptom control over the day",
        "IR formulation allows flexible dosing and fine-tuning",
        "May be combined with behavioral interventions for optimal ADHD management"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Adderall Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "American Academy of Pediatrics ADHD Guidelines",
          "url": "https://pediatrics.aappublications.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Mixed Amphetamine Salts (Adderall): ADHD & Narcolepsy Treatment",
    "description": "Comprehensive guide to mixed amphetamine salts (Adderall), including dosing, side effects, interactions, and monitoring for ADHD and narcolepsy."
  }
}
